Wales has become the first country in the world to launch specialized Intensive Learning Academies (ILAs) that will deliver transformational training and support across preventative health, value-based health and care, and innovations in health and social care.
Welsh universities have created a range of flexible courses that include degree-level opportunities within these growing fields. They are open for professionals from the health and social care, and life sciences sectors across the globe to learn together.
Led by Swansea University and Bangor University, the ILAs are also delivering research and tailor-made consultancy services. This will support individual organizations to identify, develop and collaborate on innovative practices that will help to meet the challenges facing health and social care.
The three ILAs will commence activities across 2021, with each specializing in a subject identified as a key future growth area for the global health and social care markets:
All courses will welcome applicants working across global health, social care, and life sciences systems. There are ILA scholarships available for those working within the health, social care and third sector within Wales and internationally, and for those who wish to retrain to join the sector.
Applications are now open for the bespoke programs, with more information available on the Life Sciences Hub Wales website.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.